Osteoarthritis Was Associated With a Faster Decline in Hippocampal Volumes in Cognitively Normal Older People

Xiang Li¹, Qiaowen Tong², Jianqing Gao³, Cailong Liu³, Alzheimer’s Disease Neuroimaging Initiative⁴ and Yangbo Liu³*

¹ Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ² Department of Neurology, Wenzhou People’s Hospital, Wenzhou, China, ³ Department of Orthopedics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Objective: To examine whether osteoarthritis (OA) is associated with a change in adjusted hippocampal volumes (HpVR: hippocampal/intracranial volume × 10³) over time among cognitively normal older people.

Methods: We examined the cross-sectional and longitudinal associations of OA with HpVR among individuals with normal cognition (NC) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. At baseline, a total of 372 individuals with NC were included.

Results: In the cross-sectional analyses of baseline data, we did not find a significant relationship between OA and HpVR among individuals with NC. However, in the longitudinal analyses, OA was significantly associated with change in HpVR over time among individuals with NC. Specifically, compared with individuals without OA, those with OA showed a faster decline in HpVR over time when controlling for other potential confounders, including age, educational attainment, gender, and APOE4 genotype.

Conclusion: OA status was significantly associated with a change in HpVR over time among individuals with NC.

Keywords: osteoarthritis, Alzheimer’s disease, hippocampal volumes, longitudinal study, normal cognition

INTRODUCTION

Osteoarthritis (OA) is a common and debilitating disease that influences one or more joints of the body (Hunter and Bierma-Zeinstra, 2019). Emerging evidence demonstrates that OA is also a risk factor for cognitive deficits (Huang et al., 2015; Chen et al., 2018; Weber et al., 2019), as nearly 40% of patients with Alzheimer’s disease (AD) have OA (Wang et al., 2018). Further, a previous preclinical study found that OA can accelerate and exacerbate AD pathologies (Kyrkanides et al., 2011), supporting the notion that OA may have a detrimental impact on AD pathogeneses. However, no previous studies have attempted to examine the association of OA with AD from the pathophysiological perspective in living humans. Additionally, it is not clear whether OA is associated with hippocampal volumes among cognitively normal older people.
We hypothesized that OA may be associated with a steeper decline in hippocampal volumes, increasing the risk of AD.

In the present study, we first examined the cross-sectional relationship between OA and baseline hippocampal volumes among cognitively normal older people. Second, we further examined the association of OA with changes in hippocampal volumes over time. The findings may help shed some light on the neuropathological mechanisms by which OA increases the risk of cognitive deficits.

**MATERIALS AND METHODS**

**Alzheimer’s Disease Neuroimaging Initiative Study**

Longitudinal data used in the present study were extracted from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database\(^1\). The primary aim of ADNI has been to investigate whether demographics, neuropsychological markers, serial MRI, positron emission tomography (PET), and other fluid biomarkers can be integrated to measure the progression of MCI and early AD. The ADNI study was approved by the institutional review board at each ADNI center, and informed written consent was obtained from each participant.

**Participants**

We included individuals who met the criteria for normal cognition (NC) and had baseline hippocampal volumes data and follow-up measurements of hippocampal volumes. In the present study, there was a total of 372 individuals with NC at baseline. A flowchart of the data selections is presented (Figure 1). Individuals with NC had a clinical dementia rating (CDR) (Morris, 1993) score of 0 and a Mini-Mental State Examination (MMSE) (Folstein et al., 1975) score of 24 or above. Participants with MCI had a CDR score of 0.5, a MMSE score of 24 or higher, objective memory decline as evidenced by the Wechsler Memory Scale Logical Memory II, and an absence of dementia. Patients with AD dementia had an MMSE score of less than 26, a CDR score of less than 0.5, and a diagnosis of probable AD dementia according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) Criteria. The numbers of individuals present at each follow-up visit are demonstrated in Table 1.

**Hippocampal Volumes**

The neuroimaging techniques used by ADNI have been described previously (Jack et al., 2008). Hippocampal volume data were extracted from the ADNI file “ADNIMERGE.csv.” To adjust for gender differences in head size, hippocampal volume ratio (HpVR, formula: hippocampal/intracranial volume \(\times 10^3\)) was used as the dependent variable in our models.

\(^1\)http://adni.loni.usc.edu

**RESULTS**

**Demographical and Clinical Variables**

Among individuals with NC, there were 79 participants with OA and 293 participants without OA (Table 1). Participants with OA were more likely to be female (63.3%) compared with those without OA (female 45.1%). In addition, participants with OA were more likely to be APOE4 carriers (38%) compared with those without OA (22.9%). However, there were no significant...
TABLE 1 | Demographics and clinical variables of the study participants.

| Clinical variables | OA− (n = 293) | OA+ (n = 79) | Statistic | p-values |
|--------------------|---------------|--------------|-----------|----------|
| Age, years         | 74.8 ± 5.36   | 74.2 ± 6.22  | 0.75 (t)  | 0.56     |
| Female sex, n (%)  | 132 (45.1)    | 50 (63.3)    | 8.3 (χ²)  | 0.004    |
| Education, years   | 16.3 ± 2.8    | 16.1 ± 2.5   | 0.62 (t)  | 0.54     |
| APOE4 +, n (%)     | 67 (22.9)     | 30 (38)      | 7.4 (χ²)  | 0.007    |
| MMSE               | 29.1 ± 1.1    | 29 ± 1.2     | 12176 (w) | 0.45     |
| ADAS-Cog 11        | 6.08 ± 2.95   | 5.75 ± 3     | 0.86 (t)  | 0.39     |
| Hippocampal volumes, mm³ | 7350 ± 899 | 7372 ± 933  | −0.19 (t) | 0.85     |
| ICV, cm³           | 1526 ± 158    | 1488 ± 160   | 1.9 (t)   | 0.06     |
| HpVR               | 4.85 ± 0.62   | 4.99 ± 0.66  | −1.7 (t)  | 0.08     |

Follow-up visits, n subjects

| Year     | OA− | OA+ |
|----------|-----|-----|
| 0 year (baseline) | 293 | 79  |
| 1 year    | 256 | 74  |
| 2 years   | 226 | 62  |
| 3 years   | 110 | 22  |
| 4 years   | 106 | 18  |
| 5 years   | 58  | 8   |
| 6 years   | 57  | 13  |
| 7 years   | 18  | 3   |
| 8 years   | 16  | 1   |
| 9 years   | 9   | 0   |
| 10 years  | 1   | 0   |

OA: osteoarthritis; MMSE: mini-mental state examination; ADAS-Cog 11: Alzheimer’s disease assessment scale-cognitive 11-item. ICV: intracranial volume; HpVR: hippocampal volume ratio (HpVR, hippocampal/intracranial volume × 10³).

FIGURE 2 | Cross-sectional association of OA with MMSE, ADAS-Cog 11, and HpVR among individuals with NC. There was no significant difference in MMSE, ADAS-Cog 11, or HpVR between the two groups (all p > 0.05). OA: osteoarthritis; MMSE: mini-mental state examination; ADAS-Cog 11: Alzheimer’s disease assessment scale-cognitive 11-item. HpVR: hippocampal volume ratio (HpVR, hippocampal/intracranial volume × 10³).
differences in other variables between the two groups (all $p > 0.05$; Table 1).

**Cross-Sectional Association of OA Status With MMSE, ADAS-Cog11, and HpVR Among Older Individuals With NC**

To examine the cross-sectional associations of OA status with MMSE, ADAS-Cog11, and HpVR, $t$-test or Wilcoxon test was conducted. As displayed in Table 1 and Figure 2, among older individuals with NC, there was no significant difference in MMSE, ADAS-Cog11, or HpVR between the two groups (all $p > 0.05$).

**Association of OA Status With Conversion From NC to MCI or AD Dementia**

The two groups (OA− vs. OA+) had a similar length of follow-up time (OA− vs. OA+ (median (IQR)): 4 (4) vs. 3 (2) years,

---

**FIGURE 3** Association of OA status with conversion from NC to MCI or AD dementia. OA status was not associated with conversion from NC to MCI or AD dementia (OA+: HR = 1.6, se = 0.28, $p = 0.09$). OA: osteoarthritis; NC: normal cognition; MCI: mild cognitive impairment; AD: Alzheimer’s disease.

**TABLE 2** Summary of linear mixed models examining the association of OA status with changes in global cognition over time among older individuals with NC.

| Predictors          | MMSE       | ADAS-Cog 11 |
|---------------------|------------|-------------|
|                     | Estimate   | SE          | $p$-values | Estimate   | SE          | $p$-values |
| Time                | 0.8185     | 0.2593      | 0.0016     | 0.7718     | 0.5405      | 0.1533     |
| OA+                 | −0.1872    | 0.1194      | 0.1168     | 0.0088     | 0.3133      | 0.9776     |
| Age                 | −0.0158    | 0.0086      | 0.0660     | 0.1045     | 0.0225      | <0.0001    |
| Female sex          | 0.2708     | 0.1009      | 0.0073     | −1.2887    | 0.2649      | <0.0001    |
| APOE4+              | −0.0303    | 0.1095      | 0.7819     | 0.3199     | 0.2871      | 0.2652     |
| Education           | 0.0747     | 0.0181      | <0.0001    | −0.0952    | 0.0478      | 0.0464     |
| OA+ × time          | 0.0009     | 0.0442      | 0.9831     | −0.0075    | 0.0921      | 0.9349     |
| Age × time          | −0.0126    | 0.0031      | 0.0001     | −0.0025    | 0.0065      | 0.6968     |
| Female sex × time   | 0.0223     | 0.0331      | 0.5002     | 0.0006     | 0.0691      | 0.9928     |
| APOE4+ × time       | −0.0765    | 0.0367      | 0.0372     | 0.2228     | 0.0766      | 0.0036     |
| Education × time    | 0.0028     | 0.0056      | 0.6137     | −0.0282    | 0.0117      | 0.0163     |

OA: osteoarthritis; MMSE: mini-mental state examination; ADAS-Cog 11: Alzheimer’s disease assessment scale-cognitive 11-item.
p = 0.07). Cox proportional hazard model was performed to examine the association of OA status with conversion from NC to cognitive impairment (MCI or AD dementia). The model was adjusted for age and gender. However, OA status was not associated with conversion from NC to MCI or AD dementia (OA+: HR = 1.6, SE = 0.28, p = 0.09; Figure 3).

**Longitudinal Association of OA Status With Changes in Global Cognition (MMSE and ADAS-Cog 11) Among Older Individuals With NC**

Terms reflecting associations with changes in global cognition over time are demonstrated in Table 2. We did not find significant differences in changes in MMSE or ADAS-Cog11 over time between the two groups after adjusting for other potential confounders (Table 2).

**Longitudinal Association of OA Status With Hippocampal Atrophy Among Older Individuals With NC**

Terms reflecting associations with a change in HpVR over time are demonstrated in Table 3. Compared with individuals without OA, those with OA showed a significantly steeper decline in HpVR (estimate: −0.0161, p = 0.0059) after adjusting for other potential confounders (Table 3 and Figure 4). Further, we also examined the association of OA status with changes in unadjusted hippocampal volumes (cm$^3$) over time among older individuals with NC. We found that OA+ was associated with a faster reduction in unadjusted hippocampal volumes (estimate = −0.0188, SE = 0.0085, t value = −2.2031, p = 0.0276) after controlling for other covariates.

In addition, there were severe drop-offs among individuals after seven years among the two groups. As shown in Supplementary Table 1 and Supplementary Figure 1, compared with individuals without OA, those with OA showed a significantly steeper decline in HpVR (estimate: −0.015, p = 0.0127) after adjusting for other potential confounders.

**DISCUSSION**

To the best of our knowledge, this is the first study to examine the cross-sectional and longitudinal associations between OA and adjusted hippocampal volumes (HpVR) among cognitively normal older people. In the cross-sectional analyses, we did

---

**TABLE 3 | Summary of linear mixed model examining the association of OA status with changes in HpVR over time among older individuals with NC.**

| Predictors | Estimate | SE | p-values |
|------------|----------|----|---------|
| Time       | 0.1336   | 0.0344 | 0.0001  |
| OA+        | 0.0954   | 0.0673 | 0.1565  |
| Age        | −0.0468  | 0.0048 | <0.0001 |
| Female sex | 0.2226   | 0.0571 | 0.0001  |
| APOE4+     | −0.0616  | 0.0165 | 0.3170  |
| Education  | −0.0369  | 0.0104 | 0.0011  |
| OA+ x time | −0.0161  | 0.0059 | 0.0069  |
| Age x time | −0.0023  | 0.0004 | <0.0001 |
| Female sex x time | −0.0200 | 0.0044 | <0.0001 |
| APOE4+ x time | −0.0260 | 0.0049 | <0.0001 |
| Education x time | 0.0004 | 0.0008 | 0.5996  |

OA: osteoarthritis; HpVR: hippocampal volume ratio (HpVR, hippocampal/intracranial volume × 10$^3$). Estimate was unstandardized value, reflecting the magnitude of change in HpVR per year.
not find a significant relationship between OA and HpVR. However, in the longitudinal analyses, there was a significant association of OA with changes in HpVR over time. Specifically, compared with individuals without OA, those with OA showed a steeper decline in HpVR even with adjustment for other covariates.

In the cross-sectional analyses, no significant relationship between OA and baseline HpVR was found among cognitively normal older people. This may be due to the low variability of HpVR in individuals with normal cognition. In the longitudinal analyses, we found that individuals with OA show a steeper decline in HpVR compared with those without OA. This finding was consistent with previous studies, suggesting that OA increases the risk of cognitive impairment (Huang et al., 2015; Chen et al., 2018; Weber et al., 2019).

Further, a previous study found that nearly 40% of patients with AD have OA (Wang et al., 2018). In the present study, we found that OA was associated with longitudinal hippocampal atrophy (an important marker of AD) among older individuals with NC, providing critical insight into the neuropathological mechanisms by which OA increases the risk of cognitive deficits.

There are several possible explanations for this finding. One possibility is that both OA and AD involve inflammation. Increasing evidence has suggested that neuroinflammation plays an important role in the pathogenesis of AD (Morales et al., 2014; Heneka et al., 2015; Zhang and Jiang, 2015). The inflammatory response drives microglia to overact and release a variety of inflammatory mediators, such as TNF-α, IL-1, and IL-6, which contribute to cell apoptosis and neuron loss (Block et al., 2007; Querfurth and LaFerla, 2010). Similarly, IL-1β and TNF-α are two important proinflammatory cytokines that may be involved in the pathogenesis of OA (Goldring et al., 1996; Westacott and Sharif, 1996; Martel-Pelletier et al., 1999). Additionally, levels of several proinflammatory cytokines in serum were found to be associated with the risk of AD dementia (Tan et al., 2007; Holmes et al., 2009). A previous preclinical study using an AD mouse model found that OA triggers neuroinflammation and subsequently accelerates AD pathology (Kyrkanides et al., 2011). Another possibility is that physical inactivity because of OA may increase the risk of AD and hippocampal atrophy. For instance, a prospective longitudinal study revealed that a higher level of physical activity can reduce the risk of cognitive decline and AD dementia among older individuals without dementia (Buchman et al., 2012). In contrast, in a community-based cohort, higher levels of physical activity were found to be positively related to hippocampal volumes (Tan et al., 2017).

There are several limitations in our study. First, the classification of OA was based on the participants’ self-report, which may yield some misclassifications due to self-report bias. The ADNI study did not apply structured questionnaires for recording participants’ medical history. Therefore, subjects without OA did not have any information about OA. This limitation may also yield some misclassifications due to self-report bias. Second, as shown in Table 1, compared with individuals without OA, those with OA were more likely to carry at least one copy of APOE4 allele, which is also associated with cognitive decline and hippocampal atrophy (Liu et al., 2016). We cannot rule out the possibility that the effect of OA on changes in HpVR may actually be due to the APOE4 genotype, though our model was adjusted for the APOE4 genotype. Third, the sample size of individuals with OA was relatively small. Further studies with larger sample sizes are needed to validate our findings. Fourth, physical inactivity is a potential mechanism by which OA may be associated with cognitive impairment. Further studies should include this variable as a potential covariate in the analysis. Finally, in the cross-sectional analysis, we only observed a marginally significant difference in HpVR between the two groups ($t = 1.9, p = 0.08$). However, in the longitudinal analysis, we detected a significant association of baseline OA status with changes in HpVR (estimate $= -0.0161, p = 0.0059$) or unadjusted hippocampal volumes (estimate $= -0.0188, p = 0.0276$) over time. Therefore, our data suggest that OA may be associated with longitudinal hippocampal atrophy.

In conclusion, we found that cognitively normal older individuals with OA show a steeper decline in HpVR compared with those without OA. Our data provide neuropathological evidence regarding the impact of OA that may help explain previously established relationships between OA and cognitive impairment.

### DATA AVAILABILITY STATEMENT

The datasets are publicly available (http://adni.loni.usc.edu).

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The ADNI study. The patients/participants provided their written informed consent to participate in this study.

### AUTHOR CONTRIBUTIONS

YL designed and supervised the study. XL, QT, JG, and CL performed the research, analyzed the data, and wrote the manuscript. All authors contributed to the article and approved the submitted version.

### FUNDING

Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun;
F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org/). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2020.00190/full#supplementary-material

REFERENCES

Block, M. L., Zecca, L., and Hong, J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nat. Rev. Neurosci.* 8, 57–69. doi: 10.1038/nrn2038

Buchman, A. S., Boyle, P. A., Yu, L., Shah, R. C., Wilson, R. S., and Bennett, D. A. (2012). Total daily physical activity and the risk of AD and cognitive decline in older adults. *Neurology* 78, 1323–1329. doi: 10.1212/wnl.0b013e318253d535

Chen, K. T., Chen, Y. C., Fan, Y. H., Lin, W. X., Lin, W. C., Wang, Y. H., et al. (2018). Rheumatic diseases are associated with a higher risk of dementia: a nation-wide, population-based, case-control study. *Int. J. Rheum. Dis.* 21, 373–380. doi: 10.1111/1756-185X.13246

Folstein, M. F., Folstein, S. E., and Mchugh, P. R. (1975). Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* 12, 189–198.

Goldring, M. B., Suen, I. F., Yamin, R., and Lai, W. F. (1996). Regulation of Collagen Gene Expression by Prostaglandins and Interleukin-1beta in Cultured Chondrocytes and Fibroblasts. *Am. J. Ther.* 3, 9–16. doi: 10.1097/00045391-199601000-00003

Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Broseron, F., Feinstein, D. L., et al. (2015). Neuroinflammation in Alzheimer’s disease. *Lancet Neurol.* 14, 388–405.

Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., et al. (2009). Systemic inflammation and disease progression in Alzheimer disease. *Neurology* 73, 768–774. doi: 10.1212/wnl.0b013e3181b6bb95

Huang, S.-W., Wang, W.-T., Chou, L.-C., Liao, C.-D., Liou, T.-H., and Lin, H.-W. (2015). Osteoarthritis increases the risk of dementia: a nationwide cohort study in Taiwan. *Sci. Rep.* 5:10145.

Hunter, D. J., and Bierma-Zeinstra, S. (2019). Osteoarthritis. *Lancet* 393, 1745–1759.

Jack, C. R. Jr., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., et al. (2008). The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. *J. Magn. Reson. Imaging* 27, 685–691.

Kyrkandides, S., Tallents, R. H., Jen-Nie, H. M., Olschowka, M. E., Johnson, R., Yang, M., et al. (2011). Osteoarthritis accelerates and exacerbates Alzheimer’s disease pathology in mice. *J. Neuroinflam.* 8:112. doi: 10.1186/1742-2094-8-112

Liu, Y., Tan, L., Wang, H. F., Liu, Y., Hao, X. K., Tan, C. C., et al. (2016). Multiple Effect of APOE genotype on clinical and neuroimaging biomarkers across Alzheimer’s disease spectrum. *Mol. Neurobiol.* 53, 4539–4547. doi: 10.1007/s12035-015-9388-7

Martel-Pelletier, J., Alaeddine, N., and Pelletier, J. P. (1999). Cytokines and their role in the pathophysiology of osteoarthritis. *Front. Biosci.* 4:D694–D703. doi: 10.2741/martel

Moraes, I., Guzman-Martinez, L., Cerda-Troncoso, C., Farias, G. A., and Maccioni, R. B. (2014). Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. *Front. Cell Neurosci.* 8:112. doi: 10.3389/fncel.2014.00112

Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 43, 2412–2414.

Querfurth, H. W., and Laferla, F. M. (2010). Alzheimer’s disease. *N. Engl. J. Med.* 362, 329–344.

Tan, Z., Beiser, A., Vasan, R., Rubenoff, R., Dinarello, C., Harris, T., et al. (2007). Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. *Neurology* 68, 1902–1908. doi: 10.1212/01.wnl.0000263217.36439.da

Tan, Z. S., Spartano, N. L., Beiser, A. S., Decarli, C., Auerbach, S. H., Vasan, R. S., et al. (2017). Physical activity, brain volume, and dementia risk: the framingham study. *J. Gerontol. A Biol. Sci. Med. Sci.* 72, 789–795.

Wang, I. H., Wu, Y. J., Tee, B. L., and Lo, R. Y. (2018). Medical comorbidity in Alzheimer’s disease: a nested case-control study. *J. Alzheimers Dis.* 63, 773–781. doi: 10.3233/jad-170786

Weber, A., Hung Mak, S., Berenbaum, F., Sellam, J., Zheng, Y.-P., Han, Y., et al. (2019). Association between osteoarthritis and increased risk of dementia: a systemic review and meta-analysis. *Medicine* 98:e14355. doi: 10.1097/md.00000000000014355

Westacott, C. I., and Sharif, M. (1996). Cytokines in osteoarthritis: mediators or markers of joint destruction? *Semin. Arthritis Rheum.* 25, 254–272. doi: 10.1016/0277-9516(96)80036-9

Zhang, F., and Jiang, L. (2015). Neuroinflammation in Alzheimer’s disease. *Neuropsychiatr. Dis. Treat.* 11, 243–256.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Tong, Gao, Liu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.